In a phase I/II trial, the personalized DNA vaccine GNOS-PV02 combined with pembrolizumab and plasmid-encoded IL12 yielded a response rate of 25% in patients with advanced hepatocellular carcinoma. The vaccine encoded up to 40 patient-specific neoantigens and had a manageable safety profile.

中文翻译：

---

个性化 DNA 疫苗可抑制 HCC

在 I/II 期试验中，个性化 DNA 疫苗 GNOS-PV02 联合 pembrolizumab 和质粒编码的 IL12 在晚期肝细胞癌患者中产生了 25% 的反应率。该疫苗编码多达 40 种患者特异性新抗原，并且具有可控的安全性。